Last updated: February 19, 2026
What is the drug represented by NDC 68382-0607?
NDC 68382-0607 corresponds to Emgality (galcanezumab), a monoclonal antibody developed by Eli Lilly. It is indicated for the prevention of migraine in adults and episodic cluster headache. Approved by the FDA in September 2018, it is administered via subcutaneous injection.
What is the current market landscape for galcanezumab?
Market Size and Growth Drivers
- The migraine treatment market exceeds USD 4 billion globally, with a steady CAGR of approximately 8% from 2021 to 2026 [1].
- The rise in migraine prevalence, especially among women aged 18-44, directly impacts demand.
- The growth of biologic therapies attracts investment in monoclonal antibody segments.
Competitive Landscape
- Key competitors include:
- Aimovig (erenumab) by Amgen/Novartis
- Reyvow (lasmiditan) by Eli Lilly
- Ubrelvy (ubrogepant) by Allergan
- Aimovig holds the largest share globally, due to earlier market entry (May 2018).
- Emgality’s efficacy and dosing schedule (monthly injections) position it favorably against competitors with more frequent dosing requirements.
Regulatory and Reimbursement Environment
- Reimbursement rates for biologics vary by country but generally favor established coverage for migraine preventives.
- The FDA approved Emgality under standard biologic pathways; similar regulatory environments exist in Europe, Canada, and Japan.
Pricing Trends
- List prices for Emgality approximate USD 575 per dose, with a monthly dose typically priced at USD 575. Annual costs range between USD 6,900 and USD 7,000 [2].
- Insurance coverage and PBMs influence net prices and patient access.
How is the price projected to evolve?
Short-term (1-3 years)
- Prices are expected to stabilize with minor fluctuations driven by formulary negotiations and rebate agreements.
- Pandemic-related supply chain disruptions posed temporary price and access challenges but recovery has occurred.
Medium to Long-term (3-5 years)
- Possible price reductions are anticipated due to increased competition, patent expirations, and biosimilar developments.
- Manufacturing cost reductions in biologics and dose optimization could lead to lower prices.
- The entry of biosimilar versions (not currently available in the US as of Q1 2023) could pressure list prices downward.
Market penetration and pricing strategies
- Intense marketing efforts by Lilly aim to increase physician adoption.
- Patient assistance programs mitigate affordability concerns, potentially stabilizing demand.
Revenue projections
- The global migraine biologics market is forecasted to reach USD 7 billion by 2026.
- Emgality’s market share is projected to grow by 10-15%, reaching USD 800 million to USD 1 billion annually by 2025 [3].
Risks affecting price projections
- Patent challenges or legal disputes could jeopardize exclusivity.
- Regulatory changes or unfavorable reimbursement policies could decrease profitability.
- Competitive innovations, such as oral migraine preventives, might diminish demand for injectable biologics.
Key Takeaways
- Emgality remains a significant player in the migraine biologic segment, with current list prices around USD 575 per dose.
- Market growth is driven by increasing migraine prevalence and biologic adoption.
- Competition and biosimilar entries will exert downward pressure on prices over the next five years.
- The drug’s market share is expected to expand, with revenues reaching USD 800 million to USD 1 billion by 2025.
- Price reductions are likely to occur in response to competitive dynamics, regulatory shifts, and manufacturing efficiencies.
FAQs
Q1: How does Emgality’s pricing compare to competitors?
A1: Emgality's list price (~USD 575 per dose) is similar to Aimovig (~USD 575) and higher than some oral or alternative therapies. Reimbursement negotiations and patient assistance programs influence actual net costs.
Q2: What factors could cause prices to decline?
A2: Entry of biosimilars, patent expirations, market competition, and policy changes could lead to decreased prices.
Q3: What is the outlook for biosimilar emergence?
A3: Biosimilars for galcanezumab are not yet approved in the US as of early 2023 but are under development in other markets. Approval could reduce prices significantly.
Q4: How does regulatory environment influence pricing?
A4: Favorable reimbursement policies and accelerated approvals facilitate market access, but policy shifts encouraging price controls could impose reductions.
Q5: Are generic versions feasible for biologics like galcanezumab?
A5: No, biosimilars are the closest equivalent, as biologics are not interchangeable with generics. Biosimilar approval and adoption depend on regulatory and clinical factors.
References
- Grand View Research. (2022). Migraine Drugs Market Size, Share & Trends.
- GoodRx. (2023). Cost of Emgality.
- MarketWatch. (2022). Global migraine biologics market forecast.
[1] Grand View Research. (2022). Migraine Drugs Market Size, Share & Trends.
[2] GoodRx. (2023). Cost of Emgality.
[3] MarketWatch. (2022). Global migraine biologics market forecast.
